Journal
REGENERATIVE MEDICINE
Volume 10, Issue 8, Pages 939-958Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/rme.15.57
Keywords
biodistribution; clinical trial; human embryonic stem cells; oligodendrocyte progenitors; preclinical safety; thoracic spinal cord injury; toxicology; tumorigenicity
Categories
Funding
- Geron Corporation or Asterias Biotherapeutics, Inc
Ask authors/readers for more resources
Aim: To characterize the preclinical safety profile of a human embryonic stem cell-derived oligodendrocyte progenitor cell therapy product (AST-OPC1) in support of its use as a treatment for spinal cord injury (SCI). Materials & methods: The phenotype and functional capacity of AST-OPC1 was characterized in vitro and in vivo. Safety and toxicology of AST-OPC1 administration was assessed in rodent models of thoracic SCI. Results: These results identify AST-OPC1 as an early-stage oligodendrocyte progenitor population capable of promoting neurite outgrowth in vitro and myelination in vivo. AST-OPC1 administration did not cause any adverse clinical observations, toxicities, allodynia or tumors. Conclusion: These results supported initiation of a Phase I clinical trial in patients with sensorimotor complete thoracic SCI.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available